Journal of Clinical Oncology, Vol 20, Issue 10
(May), 2002: 2520-2529
© 2002 American Society for Clinical Oncology
Effect of Prevention Strategies on Survival and Quality-Adjusted Survival of Women With BRCA1/2 Mutations: An Updated Decision Analysis
By Victor R. Grann,
Judith S. Jacobson,
Dustin Thomason,
Dawn Hershman,
Daniel F. Heitjan,
Alfred I. Neugut
From the Herbert Irving Comprehensive Cancer Center, Department of Medicine, and Joseph L. Mailman School of Public Health, College of Physicians and Surgeons, Columbia University, New York, NY.
Address reprint requests to Victor Grann, MD, MPH, FACP, Herbert Irving Comprehensive Cancer Center, Columbia University, PH18-201A, 630 W 168th St, New York, NY 10032; email: VRG2{at}columbia.edu
PURPOSE: This study updates findings regarding the effects of prophylactic surgery, chemoprevention, and surveillance on the survival and quality-adjusted survival of women who test positive for BRCA1/2 mutations.
MATERIALS AND METHODS: Markov modeling of outcomes was performed in a simulated cohort of 30-year-old women who tested positive for BRCA1/2 mutations. The model incorporated breast and ovarian cancer incidence rates from the literature and mortality rates from the Surveillance, Epidemiology, and End Results Program. Quality adjustment of survival estimates were obtained from a survey of women aged 33 to 50 years. Sensitivity analyses were performed of varied assumptions regarding timing and effects of preventive measures on cancer incidence and adverse effects.
RESULTS: A 30-year-old woman could prolong her survival beyond that associated with surveillance alone by use of preventive measures: 1.8 years with tamoxifen, 2.6 years with prophylactic oophorectomy, 4.6 years with both tamoxifen and prophylactic oophorectomy, 3.5 years with prophylactic mastectomy, and 4.9 years with both surgeries. She could prolong her quality-adjusted survival by 2.8 years with tamoxifen, 4.4 years with prophylactic oophorectomy, 6.3 years with tamoxifen and oophorectomy, and 2.6 years with mastectomy, or with both surgeries. The benefits of all of these strategies would decrease if they were initiated at later ages.
CONCLUSION: Women who test positive for BRCA1/2 mutations may derive greater survival and quality adjusted survival benefits than previously reported from chemoprevention, prophylactic surgery, or a combination. Observational studies and clinical trials are needed to verify the results of this analysis of the long-term benefits of preventive strategies among BRCA1/2-positive women.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
T. R. Rebbeck, N. D. Kauff, and S. M. Domchek
Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
J Natl Cancer Inst,
January 21, 2009;
101(2):
80 - 87.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Lowy and J. P. Gaudilliere
Localizing the Global: Testing for Hereditary Risks of Breast Cancer
Science Technology Human Values,
May 1, 2008;
33(3):
299 - 325.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. I. Brandt-Rauf, V. H. Raveis, N. F. Drummond, J. A. Conte, and S. M. Rothman
Ashkenazi Jews and Breast Cancer: The Consequences of Linking Ethnic Identity to Genetic Disease
Am J Public Health,
November 1, 2006;
96(11):
1979 - 1988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Guillem, W. C. Wood, J. F. Moley, A. Berchuck, B. Y. Karlan, D. G. Mutch, R. F. Gagel, J. Weitzel, M. Morrow, B. L. Weber, et al.
ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes
J. Clin. Oncol.,
October 1, 2006;
24(28):
4642 - 4660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Plevritis, A. W. Kurian, B. M. Sigal, B. L. Daniel, D. M. Ikeda, F. E. Stockdale, and A. M. Garber
Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
JAMA,
May 24, 2006;
295(20):
2374 - 2384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Anderson, J. S. Jacobson, D. F. Heitjan, J. G. Zivin, D. Hershman, A. I. Neugut, and V. R. Grann
Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Ann Intern Med,
March 21, 2006;
144(6):
397 - 406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Armstrong, E. Micco, A. Carney, J. Stopfer, and M. Putt
Racial Differences in the Use of BRCA1/2 Testing Among Women With a Family History of Breast or Ovarian Cancer
JAMA,
April 13, 2005;
293(14):
1729 - 1736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Eisinger, L. Huiart, and H. Sobol
The Choice of Bilateral Prophylactic Mastectomy
J. Clin. Oncol.,
February 20, 2005;
23(6):
1330 - 1331.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.S. van Roosmalen, P.F.M. Stalmeier, L.C.G. Verhoef, J.E.H.M. Hoekstra-Weebers, J.C. Oosterwijk, N. Hoogerbrugge, U. Moog, and W.A.J. van Daal
Randomized Trial of a Shared Decision-Making Intervention Consisting of Trade-Offs and Individualized Treatment Information for BRCA1/2 Mutation Carriers
J. Clin. Oncol.,
August 15, 2004;
22(16):
3293 - 3301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Balmana, E M Stoffel, K M Emmons, J E Garber, and S Syngal
Comparison of motivations and concerns for genetic testing in hereditary colorectal and breast cancer syndromes
J. Med. Genet.,
April 1, 2004;
41(4):
e44 - e44.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Armstrong, J. S. Schwartz, T. Randall, S. C. Rubin, and B. Weber
Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With BRCA1/2 Mutations: A Decision Analysis
J. Clin. Oncol.,
March 15, 2004;
22(6):
1045 - 1054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Schwartz, E. Kaufman, B. N. Peshkin, C. Isaacs, C. Hughes, T. DeMarco, C. Finch, and C. Lerman
Bilateral Prophylactic Oophorectomy and Ovarian Cancer Screening Following BRCA1/BRCA2 Mutation Testing
J. Clin. Oncol.,
November 1, 2003;
21(21):
4034 - 4041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
